David B. Solit

David B. Solit, MD, is a Physician Scientist at Memorial Sloan Kettering Cancer Center with leadership roles including Co-Director of the Marie-Josée & Henry R. Kravis Center for Molecular Oncology and affiliations in the Human Oncology & Pathogenesis Program, Department of Medicine, and Gerstner Sloan Kettering Graduate School. His research focuses on genomic analysis of cancer mutations, therapeutic resistance mechanisms, and precision oncology applications.

• Education: MD from University of Pennsylvania
• Affiliations:
  • Marie-Josée & Henry R. Kravis Center for Molecular Oncology
  • Human Oncology & Pathogenesis Program
  • Department of Medicine
  • Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center
  • Gerstner Sloan Kettering Graduate School of Biomedical Sciences

Dr. Solit's work investigates lineage-specific cancer dependencies, including:

• Genomic drivers of bladder cancer progression
• Mechanisms of resistance to RAF/MEK inhibitors
• Homologous recombination deficiency in prostate cancer
• ERK and PARP inhibition strategies
• Molecular subtyping of urothelial carcinoma
• Circulating tumor DNA applications

His research integrates whole genome sequencing and patient-derived models to identify therapeutic vulnerabilities.

Recent publications analyze ctDNA applications in metastatic breast cancer, genomic predictors for urothelial staging, and lineage plasticity in drug target expression. Key trends show emphasis on translational genomics, biomarker discovery, and machine learning applications in cancer treatment.

• 2011 - Member, American Society for Clinical Investigation
• 2007 - Louise & Allston Boyer Young Investigator Award
• 2007 - Kimmel Scholar, Sidney Kimmel Foundation
• 2002 - ASCO Career Development Award
• 2001 - ASC Young Investigator Award
• 2001 - Doris Duke Translational Award
• 2000 - NIH Clinical Scholars Research Fellow

Dr. Solit leads a multidisciplinary team including lab members in genomic analysis, computational biology, and clinical research. His lab maintains collaborations with institutions for global access to genomic profiling in rare cancers and participates in molecular tumor boards for clinical implementation of genomic data.